Table 1.
Oncological management and laboratory investigations
| 06/2016 | 07/2016§ | 08/2016 | 09/2016¶ | 11/2016 | 02/2017 | 05/2017 | 01/2018 | 03/2018 | |
|---|---|---|---|---|---|---|---|---|---|
| Oncological treatment | CT | CT & Z | CT | CT & Z | CT | ET | ET | ET | ET |
| FGF23 (u/ml) | – | – | – | – | 311 | 146 | 146 | 121 | – |
| ALP (U/L) | 138 | 250 | 353 | 144 | 136 | 173 | 105 | 96 | 108 |
| PTH (ng/l) | 343 | – | 176 | 322 | 406 | 59 | 61 | 52 | – |
| 25-HD (nmol/l) | 52 | – | 66 | 84 | 57 | – | 69 | 79 | – |
| Calcium (mmol/l) | 1.85 | 1.93 | 2.11 | 1.91 | 2.11 | 2.17 | 2.24 | 2.34 | 2.20 |
| Phosphate (mmol/l) | 0.60 | <0.32 | 0.41 | 0.49 | 0.70 | 1.27 | 1.29 | 1.02 | 1.03 |
| Ca153 (ku/l) | 4235 | – | 4019 | – | 2632 | 1524 | 1220 | 1430 | 1531 |
| CEA (μg/l) | 115 | – | 117 | – | 76 | 80 | 87 | 123 | 134 |
Abbreviations: CT chemotherapy, Z zoledronic acid, ET endocrine treatment, FGF23 fibroblast growth factor 23, ALP alkaline phosphatase, PTH parathyroid hormone, 25-HD 25-hydroxyvitamin D, CEA carcinoembryonic antigen
§ results obtained 6 days after the administration of zoledronic acid; ¶ results obtained 3 weeks after the administration of zoledronic acid